

---

## Pilocarpine

**Type of Posting:** Notice of Intent to Revise

**Posting Date:** 30– August –2019

**Targeted Official Date:** 01–May–2021, USP 2021, Issue 1

**Expert Committee:** Chemical Medicines Monographs 3

In accordance with section 7.04 (c) of the 2015–2020 Rules and Procedures of the Council of Experts, this is to provide notice that the Chemical Medicines Monographs 3 Expert Committee intends to revise the Pilocarpine monograph.

USP may propose to omit a monograph from the USP-NF if the article is no longer marketed in the United States and where the monograph is not necessary to serve a public health need. Monographs may also be proposed for omission to address safety concerns. Based on evaluation of the monograph, the USP Chemical Medicines Monographs 5 Expert Committee has determined that the Pilocarpine monograph should be proposed for omission in the *Pharmacopeial Forum* (PF).

USP Pilocarpine RS, associated with this monograph, may become unavailable prior to the monograph omission becoming official. USP does not intend to develop a replacement lot for USP Pilocarpine RS in anticipation of the omission of this monograph.

It is anticipated that the proposed revision will be published in *PF* 46(1) [Jan–Feb 2020].

Should you have any questions, please contact Morgan Puderbaugh, Senior Scientific Liaison (301–816–8373 or [mxp@usp.org](mailto:mxp@usp.org)).

---

---